PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR HYPEREOSINOPHILIC SYNDROME

摘要

The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFR±-induced or TEL-PDGFR²-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilc syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome, chronic eosinophilic leukemia and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIP1L1-PDGFR±, TEL-PDGFR² or similar mutations that activate PDGFR.